186 related articles for article (PubMed ID: 36090034)
1.
Ullah H; Zhang B; Sharma NK; McCrea PD; Srivastava Y
Front Mol Biosci; 2022; 9():981020. PubMed ID: 36090034
[TBL] [Abstract][Full Text] [Related]
2. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
3. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
4. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
[TBL] [Abstract][Full Text] [Related]
5. Distinct gene expression pattern of RUNX1 mutations coordinated by target repression and promoter hypermethylation in acute myeloid leukemia.
Li J; Jin W; Tan Y; Wang B; Wang X; Zhao M; Wang K
Front Med; 2022 Aug; 16(4):627-636. PubMed ID: 34958450
[TBL] [Abstract][Full Text] [Related]
6. Identification of Key Genes and Pathways Associated with RUNX1 Mutations in Acute Myeloid Leukemia Using Bioinformatics Analysis.
Zhu F; Huang R; Li J; Liao X; Huang Y; Lai Y
Med Sci Monit; 2018 Oct; 24():7100-7108. PubMed ID: 30289875
[TBL] [Abstract][Full Text] [Related]
7. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
[TBL] [Abstract][Full Text] [Related]
8. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
9. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
Simon L; Spinella JF; Yao CY; Lavallée VP; Boivin I; Boucher G; Audemard E; Bordeleau ME; Lemieux S; Hébert J; Sauvageau G
Blood; 2020 May; 135(21):1882-1886. PubMed ID: 32315381
[TBL] [Abstract][Full Text] [Related]
10.
Bellissimo DC; Speck NA
Front Cell Dev Biol; 2017; 5():111. PubMed ID: 29326930
[No Abstract] [Full Text] [Related]
11. Frequency and Clinicopathologic Features of RUNX1 Mutations in Patients With Acute Myeloid Leukemia Not Otherwise Specified.
You E; Cho YU; Jang S; Seo EJ; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park YM; Lee JK; Park CJ
Am J Clin Pathol; 2017 Jul; 148(1):64-72. PubMed ID: 28927163
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
Bluteau D; Gilles L; Hilpert M; Antony-Debré I; James C; Debili N; Camara-Clayette V; Wagner-Ballon O; Cordette-Lagarde V; Robert T; Ripoche H; Gonin P; Swierczek S; Prchal J; Vainchenker W; Favier R; Raslova H
Blood; 2011 Dec; 118(24):6310-20. PubMed ID: 21725049
[TBL] [Abstract][Full Text] [Related]
13. Chemogenomic Landscape of
Simon L; Lavallée VP; Bordeleau ME; Krosl J; Baccelli I; Boucher G; Lehnertz B; Chagraoui J; MacRae T; Ruel R; Chantigny Y; Lemieux S; Marinier A; Hébert J; Sauvageau G
Clin Cancer Res; 2017 Nov; 23(22):6969-6981. PubMed ID: 28855357
[No Abstract] [Full Text] [Related]
14. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel Runx1 (AML1) translocation partner genes SH3D19, YTHDf2, and ZNF687 in acute myeloid leukemia.
Nguyen TT; Ma LN; Slovak ML; Bangs CD; Cherry AM; Arber DA
Genes Chromosomes Cancer; 2006 Oct; 45(10):918-32. PubMed ID: 16858696
[TBL] [Abstract][Full Text] [Related]
16. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.
Tang JL; Hou HA; Chen CY; Liu CY; Chou WC; Tseng MH; Huang CF; Lee FY; Liu MC; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Lin LI; Tien HF
Blood; 2009 Dec; 114(26):5352-61. PubMed ID: 19808697
[TBL] [Abstract][Full Text] [Related]
17. RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients.
Rehman A; Akram AM; Chaudhary A; Sheikh N; Hussain Z; Alsanie WF; Rehman RA; Hameed N; Saleem T; Zafar A; Absar M; Iqbal Z; Alhazmi A; Baeshen HA; Mohammedsaleh ZM; Qamer S; Sayed S; Gaber A
Saudi J Biol Sci; 2021 Sep; 28(9):4845-4851. PubMed ID: 34466057
[TBL] [Abstract][Full Text] [Related]
18.
Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
[No Abstract] [Full Text] [Related]
19. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21).
Lu L; Wen Y; Yao Y; Chen F; Wang G; Wu F; Wu J; Narayanan P; Redell M; Mo Q; Song Y
Theranostics; 2018; 8(8):2189-2201. PubMed ID: 29721072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]